Global GalNAc-based Drug Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global GalNAc-based Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for GalNAc-based Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for GalNAc-based Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for GalNAc-based Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of GalNAc-based Drug include Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Novartis, Novo Nordisk (Dicerna), Hitgen (Leaderna Therapeutics Ltd.), Silence Therapeutics, Ionis, Arrowhead and Arbutus, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GalNAc-based Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GalNAc-based Drug.
The GalNAc-based Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GalNAc-based Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
GalNAc-based Drug Segment by Company
Suzhou Ribo Life Science Co., Ltd
Sirnaomics
Novartis
Novo Nordisk (Dicerna)
Hitgen (Leaderna Therapeutics Ltd.)
Silence Therapeutics
Ionis
Arrowhead
Arbutus
Alnylam Pharmaceuticals
GalNAc-based Drug Segment by Type
siRNA Based
ASO Based
GalNAc-based Drug Segment by Application
Metabolic Diseases
Neurological Diseases
Cardiovascular Diseases
Other
GalNAc-based Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GalNAc-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GalNAc-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GalNAc-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of GalNAc-based Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global GalNAc-based Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for GalNAc-based Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for GalNAc-based Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for GalNAc-based Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of GalNAc-based Drug include Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Novartis, Novo Nordisk (Dicerna), Hitgen (Leaderna Therapeutics Ltd.), Silence Therapeutics, Ionis, Arrowhead and Arbutus, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GalNAc-based Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GalNAc-based Drug.
The GalNAc-based Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GalNAc-based Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
GalNAc-based Drug Segment by Company
Suzhou Ribo Life Science Co., Ltd
Sirnaomics
Novartis
Novo Nordisk (Dicerna)
Hitgen (Leaderna Therapeutics Ltd.)
Silence Therapeutics
Ionis
Arrowhead
Arbutus
Alnylam Pharmaceuticals
GalNAc-based Drug Segment by Type
siRNA Based
ASO Based
GalNAc-based Drug Segment by Application
Metabolic Diseases
Neurological Diseases
Cardiovascular Diseases
Other
GalNAc-based Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GalNAc-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GalNAc-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GalNAc-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of GalNAc-based Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
102 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global GalNAc-based Drug Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global GalNAc-based Drug Market Size by Region (2020-2031)
- 1.4.1 Global GalNAc-based Drug Market Size by Region (2020-2025)
- 1.4.2 Global GalNAc-based Drug Market Size by Region (2026-2031)
- 1.5 Key Regions GalNAc-based Drug Market Size (2020-2031)
- 1.5.1 North America GalNAc-based Drug Market Size Growth Rate (2020-2031)
- 1.5.2 Europe GalNAc-based Drug Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific GalNAc-based Drug Market Size Growth Rate (2020-2031)
- 1.5.4 South America GalNAc-based Drug Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa GalNAc-based Drug Market Size Growth Rate (2020-2031)
- 2 GalNAc-based Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 siRNA Based
- 2.1.2 ASO Based
- 2.2 Global GalNAc-based Drug Market Size by Type
- 2.2.1 Global GalNAc-based Drug Market Size Overview by Type (2020-2031)
- 2.2.2 Global GalNAc-based Drug Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global GalNAc-based Drug Market Size Forecasted by Type (2026-2031)
- 2.3 Global GalNAc-based Drug Market Size by Regions
- 2.3.1 North America GalNAc-based Drug Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe GalNAc-based Drug Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific GalNAc-based Drug Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America GalNAc-based Drug Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa GalNAc-based Drug Market Size Breakdown by Type (2020-2025)
- 3 GalNAc-based Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Metabolic Diseases
- 3.1.2 Neurological Diseases
- 3.1.3 Cardiovascular Diseases
- 3.1.4 Other
- 3.2 Global GalNAc-based Drug Market Size by Application
- 3.2.1 Global GalNAc-based Drug Market Size Overview by Application (2020-2031)
- 3.2.2 Global GalNAc-based Drug Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global GalNAc-based Drug Market Size Forecasted by Application (2026-2031)
- 3.3 Global GalNAc-based Drug Market Size by Regions
- 3.3.1 North America GalNAc-based Drug Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe GalNAc-based Drug Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific GalNAc-based Drug Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America GalNAc-based Drug Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa GalNAc-based Drug Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 GalNAc-based Drug Industry Trends
- 4.2 GalNAc-based Drug Industry Drivers
- 4.3 GalNAc-based Drug Industry Opportunities and Challenges
- 4.4 GalNAc-based Drug Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by GalNAc-based Drug Revenue (2020-2025)
- 5.2 Global GalNAc-based Drug Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global GalNAc-based Drug Key Company Headquarters & Area Served
- 5.4 Global GalNAc-based Drug Company, Product Type & Application
- 5.5 Global GalNAc-based Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global GalNAc-based Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 GalNAc-based Drug Players Market Share by Revenue in 2024
- 5.6.3 2024 GalNAc-based Drug Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 Suzhou Ribo Life Science Co., Ltd
- 6.1.1 Suzhou Ribo Life Science Co., Ltd Comapny Information
- 6.1.2 Suzhou Ribo Life Science Co., Ltd Business Overview
- 6.1.3 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Portfolio
- 6.1.5 Suzhou Ribo Life Science Co., Ltd Recent Developments
- 6.2 Sirnaomics
- 6.2.1 Sirnaomics Comapny Information
- 6.2.2 Sirnaomics Business Overview
- 6.2.3 Sirnaomics GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Sirnaomics GalNAc-based Drug Product Portfolio
- 6.2.5 Sirnaomics Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Comapny Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 Novartis GalNAc-based Drug Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Novo Nordisk (Dicerna)
- 6.4.1 Novo Nordisk (Dicerna) Comapny Information
- 6.4.2 Novo Nordisk (Dicerna) Business Overview
- 6.4.3 Novo Nordisk (Dicerna) GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Novo Nordisk (Dicerna) GalNAc-based Drug Product Portfolio
- 6.4.5 Novo Nordisk (Dicerna) Recent Developments
- 6.5 Hitgen (Leaderna Therapeutics Ltd.)
- 6.5.1 Hitgen (Leaderna Therapeutics Ltd.) Comapny Information
- 6.5.2 Hitgen (Leaderna Therapeutics Ltd.) Business Overview
- 6.5.3 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Portfolio
- 6.5.5 Hitgen (Leaderna Therapeutics Ltd.) Recent Developments
- 6.6 Silence Therapeutics
- 6.6.1 Silence Therapeutics Comapny Information
- 6.6.2 Silence Therapeutics Business Overview
- 6.6.3 Silence Therapeutics GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 Silence Therapeutics GalNAc-based Drug Product Portfolio
- 6.6.5 Silence Therapeutics Recent Developments
- 6.7 Ionis
- 6.7.1 Ionis Comapny Information
- 6.7.2 Ionis Business Overview
- 6.7.3 Ionis GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.7.4 Ionis GalNAc-based Drug Product Portfolio
- 6.7.5 Ionis Recent Developments
- 6.8 Arrowhead
- 6.8.1 Arrowhead Comapny Information
- 6.8.2 Arrowhead Business Overview
- 6.8.3 Arrowhead GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.8.4 Arrowhead GalNAc-based Drug Product Portfolio
- 6.8.5 Arrowhead Recent Developments
- 6.9 Arbutus
- 6.9.1 Arbutus Comapny Information
- 6.9.2 Arbutus Business Overview
- 6.9.3 Arbutus GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.9.4 Arbutus GalNAc-based Drug Product Portfolio
- 6.9.5 Arbutus Recent Developments
- 6.10 Alnylam Pharmaceuticals
- 6.10.1 Alnylam Pharmaceuticals Comapny Information
- 6.10.2 Alnylam Pharmaceuticals Business Overview
- 6.10.3 Alnylam Pharmaceuticals GalNAc-based Drug Revenue, Global Share and Gross Margin (2020-2025)
- 6.10.4 Alnylam Pharmaceuticals GalNAc-based Drug Product Portfolio
- 6.10.5 Alnylam Pharmaceuticals Recent Developments
- 7 North America
- 7.1 North America GalNAc-based Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America GalNAc-based Drug Market Size by Country (2020-2025)
- 7.3 North America GalNAc-based Drug Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe GalNAc-based Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe GalNAc-based Drug Market Size by Country (2020-2025)
- 8.3 Europe GalNAc-based Drug Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific GalNAc-based Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific GalNAc-based Drug Market Size by Country (2020-2025)
- 9.3 Asia-Pacific GalNAc-based Drug Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America GalNAc-based Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America GalNAc-based Drug Market Size by Country (2020-2025)
- 10.3 South America GalNAc-based Drug Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa GalNAc-based Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa GalNAc-based Drug Market Size by Country (2020-2025)
- 11.3 Middle East & Africa GalNAc-based Drug Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
